Inflammation and Protein-Energy Wasting in the Uremic Milieu

Contributions to Nephrology

Volumn 191, Issue , 2017, Pages 58-71

  Jankowska, Magdalena ^a   Cobo, Gabriela ^b   Lindholm, Bengt ^c   Stenvinkel, Peter ^c  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b HOSPITAL EUGENIO ESPEJO   (Ecuador)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC KIDNEY FAILURE; COMPLICATION; HEMODIALYSIS; HUMAN; INFLAMMATION; PROCEDURES; PROTEIN CALORIE MALNUTRITION; TRENDS; UREMIA;

HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; PROTEIN-ENERGY MALNUTRITION; RENAL DIALYSIS; UREMIA;

EID: 85029532763     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000479256     Document Type: Article

References (41)

1. Stenvinkel P: Chronic kidney disease: A public health priority and harbinger of premature cardiovascular disease. J Intern Med 2010; 268: 456-467.
2. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911.
3. Pecoits-Filho R, Lindholm B, Stenvinkel P: The malnutrition, inflammation, and atherosclerosis (MIA) syndrome-The heart of the matter. Nephrol Dial Transplant 2002; 17(suppl 11):28-31.
4. Kooman JP, Kotanko P, Schols AM, Shiels PG, Stenvinkel P: Chronic kidney disease and premature ageing. Nat Rev Nephrol 2014; 10: 732-742.
5. Medzhitov R: Origin and physiological roles of inflammation. Nature 2008; 454: 428-435.
6. Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P: Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003; 41: 1212-1218.
7. Carrero JJ, Stenvinkel P: Inflammation in end-stage renal disease-what have we learned in 10 years? Semin Dial 2010; 23: 498-509.
8. Villa G, Zaragoza JJ, Sharma A, Neri M, De Gaudio AR, Ronco C: Cytokine removal with high cut-off membrane: review of literature. Blood Purif 2014; 38: 167-173.
9. Schindler R, Boenisch O, Fischer C, Frei U: Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol 2000; 53: 452-459.
10. Memoli B, Minutolo R, Bisesti V, Postiglione L, Conti A, Marzano L, Capuano A, Andreucci M, Balletta MM, Guida B, Tetta C; Collaborative Study Group on SMC Membrane: Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am J Kidney Dis 2002; 39: 266-273.
11. den Hoedt CH, Bots ML, Grooteman MP, van der Weerd NC, Mazairac AH, Penne EL, Levesque R, ter Wee PM, Nube MJ, Blankestijn PJ, van den Dorpel MA; CONTRAST Investigators: Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis. Kidney Int 2014; 86: 423-432.
12. Banerjee T, Kim SJ, Astor B, Shafi T, Coresh J, Powe NR: Vascular access type, inflammatory markers, and mortality in incident hemodialysis patients: The Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J Kidney Dis 2014; 64: 954-961.
13. Dukkipati R, Molnar MZ, Park J, Jing J, Kovesdy CP, Kajani R, Kalantar-Zadeh K: Association of vascular access type with inflammatory marker levels in maintenance hemodialysis patients. Semin Dial 2014; 27: 415-423.
14. Ikizler TA, Cano NJ, Franch H, Fouque D, Himmelfarb J, Kalantar-Zadeh K, Kuhlmann MK, Stenvinkel P, TerWee P, Teta D, Wang AY, Wanner C; International Society of Renal Nutrition and Metabolism: Prevention and treatment of protein energy wasting in chronic kidney disease patients: A consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int 2013; 84: 1096-1107.
15. Stenvinkel P, Heimburger O, Lindholm B: Wasting, but not malnutrition, predicts cardiovascular mortality in end-stage renal disease. Nephrol Dial Transplant 2004; 19: 2181-2183.
16. Pupim LB, Ikizler TA: Uremic malnutrition: new insights into an old problem. Semin Dial 2003; 16: 224-232.
17. Carrero JJ, Stenvinkel P, Cuppari L, Ikizler TA, Kalantar-Zadeh K, Kaysen G, Mitch WE, Price SR, Wanner C, Wang AY, ter Wee P, Franch HA: Etiology of the protein-energy wasting syndrome in chronic kidney disease: A consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr 2013; 23: 77-90.
18. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P: Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17: 1684-1688.
19. Carrero JJ, Chmielewski M, Axelsson J, Snaedal S, Heimburger O, Barany P, Suliman ME, Lindholm B, Stenvinkel P, Qureshi AR: Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. Clin Nutr 2008; 27: 557-564.
20. Stenvinkel P: Can treating persistent inflammation limit protein energy wasting? Semin Dial 2013; 26: 16-19.
21. Carrero JJ, Qureshi AR, Axelsson J, Avesani CM, Suliman ME, Kato S, Barany P, Snaedal-Jonsdottir S, Alvestrand A, Heimburger O, Lindholm B, Stenvinkel P: Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr 2007; 85: 695-701.
22. Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD: Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80: 299-307.
23. Delano MJ, Moldawer LL: The origins of cachexia in acute and chronic inflammatory diseases. Nutr Clin Pract 2006; 21: 68-81.
24. Pupim LB, Flakoll PJ, Majchrzak KM, Aftab Guy DL, Stenvinkel P, Ikizler TA: Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. Kidney Int 2005; 68: 1857-1865.
25. Pupim LB, Heimburger O, Qureshi AR, Ikizler TA, Stenvinkel P: Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. Kidney Int 2005; 68: 2368-2374.
26. Garibotto G, Fiorini F, Sala MR, Marchelli M, Verzola D, Rossi D, Sofia A: Amino acid loss with polyethersulfone. Contrib Nephrol 2003: 59-67.
27. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W; European Uremic Toxin Work Group (EUTox): Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943.
28. Castillo-Rodriguez E, Pizarro-Sanchez S, Sanz AB, Ramos AM, Sanchez-Nino MD, Martin-Cleary C, Fernandez-Fernandez B, Ortiz A: Inflammatory Cytokines as Uremic Toxins: "Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son". Toxins (Basel) 2017; 9:pii:E114.
29. Viana JL, Kosmadakis GC, Watson EL, Bevington A, Feehally J, Bishop NC, Smith AC: Evidence for anti-inflammatory effects of exercise in CKD. J Am Soc Nephrol 2014; 25: 2121-2130.
30. Machowska A, Carrero JJ, Lindholm B, Stenvinkel P: Therapeutics targeting persistent inflammation in chronic kidney disease. Transl Res 2016; 167: 204-213.
31. Gamboa JL, Pretorius M, Todd-Tzanetos DR, Luther JM, Yu C, Ikizler TA, Brown NJ: Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. J Am Soc Nephrol 2012; 23: 334-342.
32. Merino A, Alvarez-Lara MA, Ramirez R, Carracedo J, Martin-Malo A, Aljama P: Losartan prevents the development of the pro-inflammatory monocytes CD14+CD16+ in haemodialysis patients. Nephrol Dial Transplant 2012; 27: 2907-2912.
33. Morishita Y, Hanawa S, Chinda J, Iimura O, Tsunematsu S, Kusano E: Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertens Res 2011; 34: 308-313.
34. Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P: Short-Term treatment with sevelamer increases serum fetuin-A concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008; 3: 61-68.
35. Sun PP, Perianayagam MC, Jaber BL: Endotoxin-binding affinity of sevelamer: A potential novel anti-inflammatory mechanism. Kidney Int Suppl 2009; 114:S20-S25.
36. Zhang YF, Zou XL, Wu J, Yu XQ, Yang X: Rosiglitazone, a peroxisome proliferator-Activated receptor (PPAR)-γ agonist, attenuates inflammation via NF-κB inhibition in lipopolysaccharide-induced peritonitis. Inflammation 2015; 38: 2105-2115.
37. Esgalhado M, Stenvinkel P, Mafra D: Nonpharmacologic Strategies to Modulate Nuclear Factor Erythroid 2-related Factor 2 Pathway in Chronic Kidney Disease. J Ren Nutr 2017; 27: 282-291.
38. Zweigart C, Boschetti-de-Fierro A, Hulko M, Nilsson LG, Beck W, Storr M, Krause B: Medium cut-off membranes-closer to the natural kidney removal function. Int J Artif Organs 2017; 40: 328-334.
39. Kirsch AH, Lyko R, Nilsson LG, Beck W, Amdahl M, Lechner P, Schneider A, Wanner C, Rosenkranz AR, Krieter DH: Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant 2017; 32: 165-172.
40. Ronco C: The rise of expanded hemodialysis. Blood Purif 2017; 44:I-VIII.
41. Kooman J, Dekker M, Usvyat LA, Kotanko P, van der Sande F, Schalkwijk CG, Shiels PG, Stenvinkel P: Inflammation and premature aging in advanced chronic kidney disease. Am J Physiol Renal Physiol 2017, in press.